ClinicalTrials.govpublic full text
Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III MSI-H/dMMR Colorectal Cancer
colorectal cancer, mismatch repair-deficient (dmmr), microsatellite instability-high (msi-h), neoadjuvant therapy, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 803345
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.